Login
Companies $TGTX
$62.74 -$0.02 (0.03%) After hours
TG THERAPEUTICS, INC. logo

TG THERAPEUTICS, INC.

tgtherapeutics.com

What Do They Do?

Sells BRIUMVI, a medicine for adults with relapsing multiple sclerosis, and develops other treatments for diseases involving B cells.

How Do They Make Money?

TG earns revenue mainly from BRIUMVI product sales, counted when delivered. Its agreement with Neuraxpharm also provides upfront and milestone payments and royalties on sales.

revenue
SegmentShareRevenue
Product
Sold outright

98%
FY2022: 95%
License Revenue
Licensed
<0.1%
FY2022: 5.5%
Milestone
0.0%
Royalty
Licensed
0.9%
Other Revenue
0.6%

Who Are Their Customers?

TG sells BRIUMVI mainly through specialty distributors; outside the U.S., Neuraxpharm commercializes the product under an agreement.

Do Revenues Turn Into Profits?

Yes. It kept 73 cents of every revenue dollar as net income in FY2025, but spent more cash than it brought in: free cash flow was −$25M.

Operating income, FY2025
20% of revenue
▲ +194% vs FY2024 ($41.9M, 13%)
Net income, FY2025
73% of revenue
▲ +1812% vs FY2024 ($23.4M, 7%)
Free cash flow, FY2025
−4% of revenue
▲ +38% (Loss) vs FY2024 (−$40.6M, −12%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +61%
vs $161.7M in Q3 FY2025
Net income
▼ −86%
vs $390.9M in Q3 FY2025
Product revenue, net share of revenue vs 98.5% in Q3 FY2025
  • Nov 9, 2026 Raised full-year revenue guidance The 2026 total global revenue target rose from approximately $950 million to approximately $1 billion.

Growing. Revenue grew 92.1x in 4 years, from $6.7M in FY2021 to $616.3M in FY2025, about 210% a year.

International commercialization The earlier report described BRIUMVI's U.S. approval and launch; the latest report also describes approvals outside the U.S. and an agreement for commercialization beyond the U.S.

Revenue over time
Product License Revenue Milestone Royalty Other Revenue
$1B$500M$0

Who Do They Compete With?

Competes with Roche Holdings and Novartis

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support